ERBB2 and triple-negative breast carcinoma: MBC was HR+ in 69 (58.5%) patients, HER2+ in 18 (15.3%) patients, HR+/HER2− in 61 (51.7%) patients, and 39 patients (33.1%) had triple negative breast cancer (TNBC).